D. Boral Capital says Enlivex Therapeutics (ENLV) debt offering, RAIN token exposure reflects 'strategically negative' shift
Tweet Send to a Friend
D. Boral Capital analyst Jason Kolbert reiterated a Hold rating on Enlivex Therapeutics (NASDAQ: ENLV)The analyst commented, "Enlivex’s latest $21M ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
